Summary Recent studies have suggested that insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) may be implicated in the development and progression of breast cancer. Prostatespecific antigen (PSA), a serine protease, may play a role in the regulation of IGFs' function through cleavage of IGFBP-3, resulting in release of active IGFs from IGFBP-3. As IGFs, IGFBPs and PSA are all present in breast cancer, possible associations among these proteins were speculated. In this study, we have measured PSA, IGF-I, IGF-II, IGFBP-1 and IGFBP-3 in tumour tissue cytosols from 200 women with primary breast cancer, and have examined relationships between IGFs or IGFBPs and PSA along with other markers, including p53 protein, steroid hormone receptors (oestrogen and progesterone), cathepsin-D, epidermal growth factor receptor, Her-2/neu protein, S-phase fraction and DNA ploidy. Correlations or associations between PSA and IGF-I, IGF-II, IGFBP-1 or IGFBP-3 were not observed. IGF-II was positively correlated with both IGFBP-3 and IGFBP-1. IGF-I was not associated with either of the two binding proteins, nor with IGF-II. Both IGF-II and IGFBP-3 were inversely associated with the oestrogen receptor, and IGFBP-3 was also positively associated with S-phase fraction. Our finding of IGF-II and IGFBP-3 in association with unfavourable prognostic indicators of breast cancer suggests that IGFs may be involved in the progression of breast cancer.
Insulin-like growth factors (IGFs), including IGF-I and IGF-I1, belong to a family of peptide hormones involved in the regulation of normal cell growth and differentiation. IGFs exert their action through binding to two types of specific receptors, one of which (IGF-I receptor) is a transmembrane protein with tyrosine kinase activity (Krywicki and Yee, 1992; Daughaday and Rotwein, 1989) .
The binding of IGFs to their receptors is modulated by a group of soluble proteins called insulin-like growth factor binding proteins (IGFBPs) . Six distinct IGFBPs have been described so far (IGFBP-1 to . Since only the free IGFs are able to interact with their cell surface receptors, IGFBPs regulate the bioavailability and bioactivity of IGFs through binding to them . IGFBP-3 may also bind to its own receptor on the cell membrane and functions independently from the IGFs (Oh et al., 1993; Valentinis et al., 1995) .
Loss of functional IGF-I receptor was shown to be associated with slow cell growth and prolonged cell cycle. Moreover, the receptor was found to be involved in cell transformation and apoptosis (LeRoith et al., 1995; . Therefore, it was speculated that IGFs may play a role in the development and progression of cancer. Experimental studies have shown that IGFs could act as mitogens and promote the growth of breast tumour cells (Arteaga et al., 1992) and that IGFBPs regulate the impact of IGFs on tumour cells . The presence of IGFs and their binding proteins in breast cancer cells has been well characterised and their relationships have been studied in both cultured breast cancer cell lines as well as breast cancer tissues (Cullen et al., 1992; Yee et al., 1991; Sheikh et al., 1992; Pekonen et al., 1992; Paik 1992) .
Responses of breast cancer cells to tamoxifen treatment were found to be associated with changes in IGFs and IGFBPs; it was shown IGF-I levels decreased and IGFBP-3 levels increased in the serum of breast cancer patients after administration of tamoxifen (Pollak et al., 1990; Lonning et al., 1992) . In animal experiments, tamoxifen was shown to suppress the expression of the IGF-I gene (Huynh et al., 1993) . The association between tamoxifen treatment and IGFs or IGFBPs suggests that the production of IGFs or IGFBPs may be regulated by steroid hormones Pollak, 1993, 1994; Owens et al., 1993; Winston et al., 1994; Manni et al., 1994) . The presence of the oestrogen receptor (ER) or the progesterone receptor (PR) has also been found to be associated with levels of both IGFs and IGFBPs in breast cancer cell lines and tissues (Figueroa et al., 1993; Yee et al., 1994) .
Prostate-specific antigen (PSA) is a glycoprotein and serine protease with chymotrypsin-like enzymatic activity. PSA has been found to be able to cleave IGFBP-3 (Cohen et al., 1992) , suggesting that PSA may regulate the function of IGFs through the digestion of IGFBP-3 (Cohen et al., 1994; Kanety et al., 1993) . Correlations between PSA and some IGFBPs have been observed in the serum of prostate cancer patients (Kanety et al., 1993) . PSA, currently used as a biochemical marker for diagnosis and management of patients with prostate cancer, was initially thought to be produced exclusively by the prostate, but recently it has been found in breast cancer tissue (Diamandis et al., 1994) . The presence of PSA in breast cancer was associated with steroid hormone receptors, and the breast cancer cell lines could produce PSA after the cells were stimulated with androgens or progestins (ELISA) , involving anti-IGF-I antibody-coated microtitration wells and a monoclonal anti-IGF-I detection antibody labelled with HRP. The IGF-I kit has a standard range of 0.1 -6 ,g 11 and a precision of < 10% coefficient of variation (CV).
The DSL IGF-II kit is a two-step immunoradiometric assay (IRMA), involving anti-IGF-II antibody-coated tubes and a radioiodinated monoclonal detection antibody. The IRMA assay has a standard range between 3 and 50 ,ug 1`. The assay's precision is < 10% CV. Both IGF-I and IGF-I1 assays require an acid -ethanol extraction step which is designed to dissociate and remove IGFBPs from the samples before analysis. The extraction procedures include sequential mixture of 50 jil sample with 450 ,ul extraction solution at room temperature for 30 min, centrifugation of the mixture at 10 000 r.p.m. for 3 min, mixture of the supernatant at 1:1 ratio with neutralisation solution, and assay of the final mixture diluted (1:5) in an assay buffer (a final dilution of sample 1: 100).
The DSL IGFBP-1 and IGFBP-3 kits are also based on ELISA principles. The assays were performed in microtitration wells coated with a highly specific anti-IGFBP-1 or IGFBP-3 antibody. The IGFBP-3 ELISA kit uses a polyclonal detection antibody, while a monoclonal antibody is used in the IGFBP-l kit. Both assays are based on a twostep assay principle and incorporate HRP as label. The calibrator ranges are between 0.25 and 25 ug 1-1 for the IGFBP-1 kit and between 2 and 100 jug 1 1 for the IGFBP-3 kit. The precision is < 10% CV for both assays.
The methods used for the measurement of ER, PR, EGFR, CATD, HER-2, SPF, DNA ploidy, p53, PSA and total protein have been described previously . Briefly, ER and PR were measured by the dextrancoated charcoal method. EGFR was determined by a radiolabelled ligand-binding assay. An EIA kit from Triton Diagnostics was used to measure CATD, and HER-2 was measured by the Western blotting technique. DNA flow cytometry was used to determine DNA content and S-phase fraction, which was defined as the percentage of cells in S phase among the diploid populations. Based on the previous study, less than 6.7% of S-phase fraction was considered a cut-off for favourable prognosis. PSA and p53 were measured by two in-house sandwich-type time-resolved immunofluorometric assays. For the samples which were used for the measurements of ER, PR, EGFR, CATD and HER-2, the total protein was determined by the Lowry method, and for those used for PSA and p53 measurement, the protein was measured by a bicinchoninic acid-based commercial kit from Pierce.
The measurements of ER, PR, EGFR, CATD, HER-2, SPF and DNA ploidy were performed in San Antonio when the specimens were collected, whereas PSA, p53, IGFs and IGFBPs were determined later in Toronto when the present study was undertaken.
Statistical analysis
As most of the data generated by the immunoassays or other analytical methods do not follow Gaussian distributions, the numerical values were analysed non-parametrically. The Spearman correlation coefficients were calculated for assessing the correlation between any two of the markers, and the Wilcoxon rank sum test was employed to compare the median concentrations between groups. The numerical data were also classified into categories, and were analysed using chi-square or Fisher's exact tests. The cut-off values for the categorical group were either based on the percentile boundary (median) or were established elsewhere . For IGFs and IGFBPs, the values were grouped into high and low categories based on the medians. PSA and p53 were classified into positive and negative groups using cut-off levels of 0.03 ng mg-' and 5 units g-1 respectively.
Positive and negative classifications were also used for ER (3 fmol mg-1), PR (5 fmol mg-1), EGFR (10 fmol mg-') and CATD (51 pmol mg-1). HER-2 was categorised into high and low groups following the method described by Tandon et al. (1989) .
Results
Because of the lack of enough sample volume in some specimens, of the 200 samples, 135 were measured for IGF-I and IGF-II, 160 were measured for IGFBP-1, and 169 were measured for IGFBP-3. The frequency distributions of the values of IGFs and IGFBPs are shown in Figures 1-4 . The numerical distributions of the four markers are demonstrated in Table I . For IGF-I, the lowest value was 0.9 ng mg-1 and the highest 52 ng mg-'. The median and mean were close, 7 and 8 ng mg-respectively. In comparison to IGF-I, the IGF-II levels were much higher, ranging from 4.2 to 72 ng mg-' with an identical median and mean value of 36 ng mg-. With regard to the two binding proteins, IGFBP-3 concentration was much higher than IGFBP-1. The values ranged from 0.02 to 6.6 ng mg-1 for IGFBP-1 and from 0.2 to 369 ng mg-' for IGFBP-3. The median values were all lower than the means for the two markers, suggesting a positive skew of the data from the normal distribution (Table I ).
The correlations between any two of these markers are shown in Table II with either of the IGFs (r = -0.08, P = 0.36 for IGF-I; r = 0.05, P = 0.54 for IGF-II). al., 1996) .
Among the two IGFs and two IGFBPs, IGF-II and IGFBP-3 were shown to have a strong positive correlation; the Spearman correlation coefficient was 0.38 (P<0.01). IGFBP-1 was also significantly correlated with IGFBP-3 (r=0.20; P=0.02). No correlation was found between the two IGFs. IGF-I did not correlate to either of the IGFBPs. A positive correlation between IGF-II and IGFBP-3 was also suggested in a study which found that the mRNA levels of IGF-II and IGFBP-3 declined after the reduction of oestrogen level, and were elevated again when the oestrogen level increased (Manni et al., 1994) .
PSA digestion of IGFBP-3 has been observed previously in seminal plasma (Cohen et al., 1992) . Experimental study showed that this digestion could result in recovery of the mitogenic effect of IGFs on prostatic cells, which was believed to be suppressed by IGFBP-3 (Cohen et al., 1994 ). An inverse correlation between IGFBP-3 and PSA was also observed in the serum of prostate cancer patients (Kanety et al., 1993) . More recently, it was found that IGF-I was able to activate the androgen receptor directly (Culig et al., 1994) . Androgen, the legitimate ligand of androgen receptor, is known to up-regulate the transcription of PSA mRNA (Young et al., 1991) . PSA was initially thought to be produced specifically by the prostate, but our recent studies demonstrated the presence of PSA in breast cancer tissue (Diamandis et al., 1994) . If PSA was a protease of IGFBP-3 in breast tissue, a correlation or association between PSA and IGFBP-3 might be expected. However, such a relationship was not observed in this study. This may suggest that the cleavage of IGFBP-3 by PSA does not occur in breast cancer or that PSA in the breast is not enzymatically active.
Other explanations for our finding of no association between PSA and IGFBP-3 in breast cancer may also exist. One of the possibilities could be the method we used to measure IGFBP-3. It is known that IGFBP-3 is present in the circulation or tissues in two major molecular forms, intact IGFBP-3 and IGFBP-3 fragments (Gargosky et al., 1992) . The fragments are the products of proteolytic cleavage by the proteases of IGFBP-3. The total amount of IGFBP-3 (intact plus fragments) may remain the same after the proteolytic process, while the ratio of the intact IGFBP-3 and its fragments undergoes substantial changes. Our method for IGFBP-3 is a sandwich-type immunoassay which quantifies both intact IGFBP-3 and IGFBP-3 fragments. The method ad m iPs -I cmer McGuire and Clark, 1992) . High percentage of SPF or aneuploid DNA is also believed to be indicative of poor prognosis. With regard to PSA, it was recently found by our group that the presence of PSA could suggest a favourable outcome of breast cancer . Combining all the findings in the study, we observed that high levels of IGF-H and IGFBP-3 tended to be related to unfavourable prognostic indicators of breast cancer. It included an inverse correlation as well as association between ER and IGF-II or IGFBP-3, and a positive correlation and association between IGFBP-3 and SPF. There was also a positive correlation but not a positive association between IGF-H and p53 and between IGFBP-3 and EGFR.
Under the overall trend of IGFs and IGFBPs in association with poor prognostic markers of breast cancer, CATD was the only exception. CATD was shown in the study to have an inverse correlation as well as association with both IGF-II and IGF-I. However, many studies have demonstrated that CATD is an indicator for poor prognosis. We were unable to find a reasonable explanation for this observation.
Our finding of IGF-II and IGFBP-3 in association with poor prognostic markers of breast cancer is consistent with the findings demonstrated by others. An inverse relationship between ER and IGFBP-3 has been reported in a number of studies (Yee et al., 1991; Manni et al., 1994; Figueroa et al., 1993; Clemmons et al., 1990) . Cell culture studies demonstrated that IGFs as mitogens could facilitate the growth of tumour cells and increase the resistance of cells to apoptosis . IGF levels were reduced in patients who responded well to tamoxifen treatment (Pollak et al., 1992 
